Matthias Alder - 20 Dec 2023 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role: Chief Executive Officer, Director
Signature: /s/ Matthias Alder
Issuer symbol: GANX
Transactions as of: 20 Dec 2023
Net transactions value: -$507
Form type: 4
Filing time: 22 Dec 2023, 16:17:28 UTC
Previous filing: 14 Dec 2023
Next filing: 25 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GANX	Common Stock	Options Exercise		+637	+13%		5,492	20 Dec 2023	Direct	F1
transaction	GANX	Common Stock	Sale	$507	-206	-3.8%	$2.46	5,286	21 Dec 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GANX	Restricted Stock Units	Options Exercise	$0	-637	-8.3%	$0.000000	7,013	20 Dec 2023	Common Stock	637		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4602 to $2.485 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The RSUs vested 25% on September 20, 2023 and the remainder vested or shall vest in 12 equal quarterly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.